Journal
BULLETIN DU CANCER
Volume 109, Issue 4, Pages 387-389Publisher
ELSEVIER MASSON, CORP OFF
DOI: 10.1016/j.bulcan.2022.01.004
Keywords
Anti-PD-1; Immunotherapy; Pembrolizumab; Triple-negative breast neoplasms